BioPharma « Terug naar discussie overzicht

Insmed, in de gaten houden

20.047 Posts, Pagina: « 1 2 3 4 5 6 ... 842 843 844 845 846 847 848 849 850 851 852 ... 999 1000 1001 1002 1003 » | Laatste
[verwijderd]
0
Press Release Source: Insmed Incorporated

Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
Tuesday June 13, 8:04 am ET

RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.


"We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."
[verwijderd]
0
Press Release Source: Insmed Incorporated

Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
Tuesday June 13, 8:04 am ET

RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.
ADVERTISEMENT




"We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."

About Insmed

Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.

Forward Looking Statements

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.
[verwijderd]
0
quote:

Rieltijm schreef:

Bijna gelijkertijd rac, beter 2x dan niet.....

Ries
zekers.koers reageert ook meteen.

Pre-Market (RT-ECN): 1.55 0.14 (9.93%)
[verwijderd]
0
quote:

rac69 schreef:

[quote=Rieltijm]
Bijna gelijkertijd rac, beter 2x dan niet.....

Ries
[/quote]

zekers.koers reageert ook meteen.

Pre-Market (RT-ECN): 1.55 0.14 (9.93%)
Yep, ziet er inderdaad een stuk gezelliger uit... maar ik kijk wel weer vanavond om 22.00 uur locale tijd (lees: hier), want met Insmed (en het verrotte beursklimaat) weet je het nooit.....
Sterkte
Ries
[verwijderd]
0
MADW (of een ander): post dit ff op Yahoo TRCA-forum, heb daar (gelukkig) geen account, volgens mij staat het er nog niet....
grinnek... sub 4 vandaag, wel zeker...!
Richard
[verwijderd]
0
Insmed gaat inderdaad de kosten verhalen op Tercica!!!

Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.

Gr. Gismo
[verwijderd]
0
Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option

Betalen die hap
Tecica vandaag onder de 3,50
[verwijderd]
0
Perfect! Hoef mij niet te verbazen!...en kosten worden waarschijnlijk verhaald op TRCA!

Geluk, F.
[verwijderd]
0
quote:

Rieltijm schreef:

MADW (of een ander): post dit ff op Yahoo TRCA-forum, heb daar (gelukkig) geen account, volgens mij staat het er nog niet....
grinnek... sub 4 vandaag, wel zeker...!
Richard
Never mind, is al opgepikt door een Insmed aanhanger.....
[verwijderd]
0
Een op meerdere fronten mooie dag vandaag!!
Het zou zo maar eens kunnen, dat de IB-ers vandaag het tapijt onder TRCA uittrekken en instappen in Insmed.
Het feit, dat ze dan hun geld kwijt zijn, heet in bedrijfstermen: sunk cost.
En ja, you win some, you lose some!

Dus nu: Lazard achterna met hun $4.

Psycho
gaat diep in de wijnkelder een bijzonder flesje uitzoeken om het te vieren
[verwijderd]
0
Eindelijk jongens, eindelijk worden we beloond met goed nieuws. En dan over 11 handelsdagen nog de update eroverheen. Groene ik zou heel snel terug gaan kopen.
[verwijderd]
0
quote:

Striker_ schreef:

ja wie liegt er nou?
trca zei dat ze het verkeerd hadden ingediend?
Insmed heeft de beste advocaten, dus welk persbericht zou het meest adequate zijn??

P.
Mark__
0
zoals ik het zie is de case niet dismissed, alleen verschoven naar een andere rechtbank. Dit ivm het rechtsgebied.
Striker_
0
hoezo de beste advocaten?
Denken jullie dat TRCA voorliegt in de SEC filings dan???

Tercica, Inc. today filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, the Honorable Saundra Brown Armstrong, dismissed on June 9, 2006 Tercica's complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica's re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists, who for purposes of the Lanham Act and related statutes are among the relevant community of consumers affected.

Of denken jullie soms ook dat ze het niet nog een keer indienen?
Wat heeft TRCA te verliezen?? juist, NIETS. Alleen nog wat meer geld van hun investeerders.
[verwijderd]
0
08:32 $ 1.55 1,000
08:32 $ 1.55 1,000
08:26 $ 1.55 800
08:16 $ 1.57 2,500
08:16 $ 1.57 1,500
08:16 $ 1.57 2,500
08:16 $ 1.57 1,500
08:13 $ 1.55 100
08:13 $ 1.55 900
08:13 $ 1.55 1,000
08:13 $ 1.55 100
08:13 $ 1.55 900
08:13 $ 1.55 1,000
08:12 $ 1.55 1,000
08:12 $ 1.55 1,000


Mark__
0
20.047 Posts, Pagina: « 1 2 3 4 5 6 ... 842 843 844 845 846 847 848 849 850 851 852 ... 999 1000 1001 1002 1003 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Direct naar Forum

Markt vandaag

 AEX
913,27  -5,99  -0,65%  13:03
 Germany40^ 22.813,40 -0,81%
 BEL 20 4.474,93 -0,29%
 Europe50^ 5.409,54 -0,76%
 US30^ 41.848,30 -0,30%
 Nasd100^ 19.613,40 -0,38%
 US500^ 5.650,04 -0,25%
 Japan225^ 37.563,80 -0,35%
 Gold spot 3.035,49 -0,34%
 EUR/USD 1,0856 -0,01%
 WTI 67,77 -0,82%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Accsys +1,68%
KPN +1,62%
PROSUS +1,26%
JDE PEET'S +0,56%
OCI +0,37%

Dalers

BESI -3,64%
Basic-Fit -2,78%
THEON INTERNAT -2,42%
ASMI -2,38%
ALLFUNDS GROUP -2,09%